Sildenafil Potentiates a cGMP-Dependent Pathway to Promote Melanoma Growth

Cell Reports

Volumn 14, Issue 11, 2016, Pages 2599-2610

  Dhayade, Sandeep ^a   Kaesler, Susanne ^a   Sinnberg, Tobias ^a   Dobrowinski, Hyazinth ^a   Peters, Stefanie ^a   Naumann, Ulrike ^b   Liu, He ^c   Hunger, Robert E ^d   Thunemann, Martin ^a   Biedermann, Tilo ^a,e   Schittek, Birgit ^a   Simon, Hans Uwe ^c   Feil, Susanne ^a   Feil, Robert ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c UNIVERSITY OF BERN   (Switzerland)

^d UNIVERSITY OF BERN   (Switzerland)

^e TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC GMP; NATRIURETIC PEPTIDE RECEPTOR B; SILDENAFIL; 1,3 BUTADIENE DERIVATIVE; 1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; CYCLIC GMP DEPENDENT PROTEIN KINASE 1; ISOPROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NATRIURETIC PEPTIDE TYPE C; NITRILE; PHOSPHODIESTERASE V; PHOSPHODIESTERASE V INHIBITOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CELL MIGRATION; CONTROLLED STUDY; DRUG ACTIVITY; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MELANOMA CELL; MOLECULAR WEIGHT; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; RISK ASSESSMENT; SIGNAL TRANSDUCTION; TUMOR VOLUME; ALLOTRANSPLANTATION; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CELL MOTION; CELL PROLIFERATION; CHEMISTRY; DRUG EFFECTS; GENETICS; MELANOMA; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; BUTADIENES; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CYCLIC GMP; CYCLIC GMP-DEPENDENT PROTEIN KINASE TYPE I; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 5; FEMALE; HUMANS; MELANOMA; MICE; MICE, INBRED C57BL; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; NATRIURETIC PEPTIDE, C-TYPE; NITRILES; PHOSPHODIESTERASE 5 INHIBITORS; PROTEIN ISOFORMS; SIGNAL TRANSDUCTION; SILDENAFIL CITRATE; TRANSPLANTATION, HOMOLOGOUS;

EID: 84962573594     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2016.02.028     Document Type: Article

References (57)

1. Aicher A., Heeschen C., Feil S., Hofmann F., Mendelsohn M.E., Feil R., Dimmeler S. cGMP-dependent protein kinase I is crucial for angiogenesis and postnatal vasculogenesis. PLoS ONE 2009, 4:e4879.
2. Arozarena I., Sanchez-Laorden B., Packer L., Hidalgo-Carcedo C., Hayward R., Viros A., Sahai E., Marais R. Oncogenic BRAF induces melanoma cell invasion by downregulating the cGMP-specific phosphodiesterase PDE5A. Cancer Cell 2011, 19:45-57.
3. Barsoum I.B., Koti M., Siemens D.R., Graham C.H. Mechanisms of hypoxia-mediated immune escape in cancer. Cancer Res. 2014, 74:7185-7190.
4. Beavo J.A., Brunton L.L. Cyclic nucleotide research -- still expanding after half a century. Nat. Rev. Mol. Cell Biol. 2002, 3:710-718.
5. Buchheit C.L., Weigel K.J., Schafer Z.T. Cancer cell survival during detachment from the ECM: multiple barriers to tumour progression. Nat. Rev. Cancer 2014, 14:632-641.
6. Cheng P.F., Dummer R., Levesque M.P. Data mining The Cancer Genome Atlas in the era of precision cancer medicine. Swiss Med. Wkly. 2015, 145:w14183.
7. Das A., Durrant D., Salloum F.N., Xi L., Kukreja R.C. PDE5 inhibitors as therapeutics for heart disease, diabetes and cancer. Pharmacol. Ther. 2015, 147:12-21.
8. Drees M., Zimmermann R., Eisenbrand G. 3',5'-Cyclic nucleotide phosphodiesterase in tumor cells as potential target for tumor growth inhibition. Cancer Res. 1993, 53:3058-3061.
9. Fajardo A.M., Piazza G.A., Tinsley H.N. The role of cyclic nucleotide signaling pathways in cancer: targets for prevention and treatment. Cancers (Basel) 2014, 6:436-458.
10. Feil R., Lohmann S.M., de Jonge H., Walter U., Hofmann F. Cyclic GMP-dependent protein kinases and the cardiovascular system: insights from genetically modified mice. Circ. Res. 2003, 93:907-916.
11. Feil R., Feil S., Hofmann F. A heretical view on the role of NO and cGMP in vascular proliferative diseases. Trends Mol. Med. 2005, 11:71-75.
12. Fiedler B., Feil R., Hofmann F., Willenbockel C., Drexler H., Smolenski A., Lohmann S.M., Wollert K.C. cGMP-dependent protein kinase type I inhibits TAB1-p38 mitogen-activated protein kinase apoptosis signaling in cardiac myocytes. J. Biol. Chem. 2006, 281:32831-32840.
13. Föller M., Feil S., Ghoreschi K., Koka S., Gerling A., Thunemann M., Hofmann F., Schuler B., Vogel J., Pichler B., et al. Anemia and splenomegaly in cGKI-deficient mice. Proc. Natl. Acad. Sci. USA 2008, 105:6771-6776.
14. Francis S.H., Corbin J.D., Bischoff E. Cyclic GMP-hydrolyzing phosphodiesterases. Handbook Exp. Pharmacol. 2009, 191:367-408.
15. Ghofrani H.A., Osterloh I.H., Grimminger F. Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond. Nat. Rev. Drug Discov. 2006, 5:689-702.
16. Gray-Schopfer V., Wellbrock C., Marais R. Melanoma biology and new targeted therapy. Nature 2007, 445:851-857.
17. Hofmann F., Feil R., Kleppisch T., Schlossmann J. Function of cGMP-dependent protein kinases as revealed by gene deletion. Physiol. Rev. 2006, 86:1-23.
18. Jaumann M., Dettling J., Gubelt M., Zimmermann U., Gerling A., Paquet-Durand F., Feil S., Wolpert S., Franz C., Varakina K., et al. cGMP-Prkg1 signaling and Pde5 inhibition shelter cochlear hair cells and hearing function. Nat. Med. 2012, 18:252-259.
19. Kemp-Harper B., Feil R. Meeting report: cGMP matters. Sci. Signal. 2008, 1:pe12.
20. Kim Y.M., Renné C., Seifert S., Schuh K., Renné T. Impaired melanoma growth in VASP deficient mice. FEBS Lett. 2011, 585:2533-2536.
21. Kong X., Wang X., Xu W., Behera S., Hellermann G., Kumar A., Lockey R.F., Mohapatra S., Mohapatra S.S. Natriuretic peptide receptor a as a novel anticancer target. Cancer Res. 2008, 68:249-256.
22. Kots A.Y., Martin E., Sharina I.G., Murad F. A short history of cGMP, guanylyl cyclases, and cGMP-dependent protein kinases. Handbook Exp. Pharmacol. 2009, 191:1-14.
23. Kuhn M. Function and dysfunction of mammalian membrane guanylyl cyclase receptors: lessons from genetic mouse models and implications for human diseases. Handbook Exp. Pharmacol. 2009, 191:47-69.
24. Kumazoe M., Sugihara K., Tsukamoto S., Huang Y., Tsurudome Y., Suzuki T., Suemasu Y., Ueda N., Yamashita S., Kim Y., et al. 67-kDa laminin receptor increases cGMP to induce cancer-selective apoptosis. J. Clin. Invest. 2013, 123:787-799.
25. Lelièvre V., Pineau N., Hu Z., Ioffe Y., Byun J.Y., Muller J.M., Waschek J.A. Proliferative actions of natriuretic peptides on neuroblastoma cells. Involvement of guanylyl cyclase and non-guanylyl cyclase pathways. J. Biol. Chem. 2001, 276:43668-43676.
26. Li W.Q., Qureshi A.A., Robinson K.C., Han J. Sildenafil use and increased risk of incident melanoma in US men: a prospective cohort study. JAMA Intern. Med. 2014, 174:964-970.
27. Lo J.A., Fisher D.E. The melanoma revolution: from UV carcinogenesis to a new era in therapeutics. Science 2014, 346:945-949.
28. Lohmann S.M., Walter U. Tracking functions of cGMP-dependent protein kinases (cGK). Front. Biosci. 2005, 10:1313-1328.
29. Marathe N., Rangaswami H., Zhuang S., Boss G.R., Pilz R.B. Pro-survival effects of 17β-estradiol on osteocytes are mediated by nitric oxide/cGMP via differential actions of cGMP-dependent protein kinases I and II. J. Biol. Chem. 2012, 287:978-988.
30. Mergia E., Koesling D., Friebe A. Genetic mouse models of the NO receptor 'soluble' guanylyl cyclases. Handbook Exp. Pharmacol. 2009, 191:33-46.
31. Meyer C., Sevko A., Ramacher M., Bazhin A.V., Falk C.S., Osen W., Borrello I., Kato M., Schadendorf D., Baniyash M., Umansky V. Chronic inflammation promotes myeloid-derived suppressor cell activation blocking antitumor immunity in transgenic mouse melanoma model. Proc. Natl. Acad. Sci. USA 2011, 108:17111-17116.
32. Miller A.J., Mihm M.C. Melanoma. N. Engl. J. Med. 2006, 355:51-65.
33. 2+ concentration via activation of cGMP-dependent protein kinase Iα. Free Radic. Biol. Med. 2012, 53:1574-1583.
34. Nojiri T., Hosoda H., Tokudome T., Miura K., Ishikane S., Otani K., Kishimoto I., Shintani Y., Inoue M., Kimura T., et al. Atrial natriuretic peptide prevents cancer metastasis through vascular endothelial cells. Proc. Natl. Acad. Sci. USA 2015, 112:4086-4091.
35. Noonan F.P., Zaidi M.R., Wolnicka-Glubisz A., Anver M.R., Bahn J., Wielgus A., Cadet J., Douki T., Mouret S., Tucker M.A., et al. Melanoma induction by ultraviolet A but not ultraviolet B radiation requires melanin pigment. Nat. Commun. 2012, 3:884.
36. Omholt K., Platz A., Kanter L., Ringborg U., Hansson J. NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression. Clin. Cancer Res. 2003, 9:6483-6488.
37. Potter L.R., Abbey-Hosch S., Dickey D.M. Natriuretic peptides, their receptors, and cyclic guanosine monophosphate-dependent signaling functions. Endocr. Rev. 2006, 27:47-72.
38. Russwurm M., Mullershausen F., Friebe A., Jäger R., Russwurm C., Koesling D. Design of fluorescence resonance energy transfer (FRET)-based cGMP indicators: a systematic approach. Biochem. J. 2007, 407:69-77.
39. Rybalkin S.D., Rybalkina I.G., Feil R., Hofmann F., Beavo J.A. Regulation of cGMP-specific phosphodiesterase (PDE5) phosphorylation in smooth muscle cells. J. Biol. Chem. 2002, 277:3310-3317.
40. Sarfati M., Mateo V., Baudet S., Rubio M., Fernandez C., Davi F., Binet J.L., Delic J., Merle-Beral H. Sildenafil and vardenafil, types 5 and 6 phosphodiesterase inhibitors, induce caspase-dependent apoptosis of B-chronic lymphocytic leukemia cells. Blood 2003, 101:265-269.
41. Schönrath K., Pan W., Klein-Szanto A.J., Braunewell K.H. Involvement of VILIP-1 (visinin-like protein) and opposite roles of cyclic AMP and GMP signaling in in vitro cell migration of murine skin squamous cell carcinoma. Mol. Carcinog. 2011, 50:319-333.
42. Serafini P., Meckel K., Kelso M., Noonan K., Califano J., Koch W., Dolcetti L., Bronte V., Borrello I. Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. J. Exp. Med. 2006, 203:2691-2702.
43. Shi Z., Tiwari A.K., Patel A.S., Fu L.W., Chen Z.S. Roles of sildenafil in enhancing drug sensitivity in cancer. Cancer Res. 2011, 71:3735-3738.
44. Shtivelman E., Davies M.Q., Hwu P., Yang J., Lotem M., Oren M., Flaherty K.T., Fisher D.E. Pathways and therapeutic targets in melanoma. Oncotarget 2014, 5:1701-1752.
45. Sullivan R.J., Flaherty K. MAP kinase signaling and inhibition in melanoma. Oncogene 2013, 32:2373-2379.
46. Thunemann M., Fomin N., Krawutschke C., Russwurm M., Feil R. Visualization of cGMP with cGi biosensors. Methods Mol. Biol. 2013, 1020:89-120.
47. Thunemann M., Wen L., Hillenbrand M., Vachaviolos A., Feil S., Ott T., Han X., Fukumura D., Jain R.K., Russwurm M., et al. Transgenic mice for cGMP imaging. Circ. Res. 2013, 113:365-371.
48. Tinsley H.N., Gary B.D., Keeton A.B., Zhang W., Abadi A.H., Reynolds R.C., Piazza G.A. Sulindac sulfide selectively inhibits growth and induces apoptosis of human breast tumor cells by phosphodiesterase 5 inhibition, elevation of cyclic GMP, and activation of protein kinase G. Mol. Cancer Ther. 2009, 8:3331-3340.
49. Valtcheva N., Nestorov P., Beck A., Russwurm M., Hillenbrand M., Weinmeister P., Feil R. The commonly used cGMP-dependent protein kinase type I (cGKI) inhibitor Rp-8-Br-PET-cGMPS can activate cGKI in vitro and in intact cells. J. Biol. Chem. 2009, 284:556-562.
50. Weber S., Bernhard D., Lukowski R., Weinmeister P., Wörner R., Wegener J.W., Valtcheva N., Feil S., Schlossmann J., Hofmann F., Feil R. Rescue of cGMP kinase I knockout mice by smooth muscle specific expression of either isozyme. Circ. Res. 2007, 101:1096-1103.
51. Weinmeister P., Lukowski R., Linder S., Traidl-Hoffmann C., Hengst L., Hofmann F., Feil R. Cyclic guanosine monophosphate-dependent protein kinase I promotes adhesion of primary vascular smooth muscle cells. Mol. Biol. Cell 2008, 19:4434-4441.
52. Weinstein J.N., Collisson E.A., Mills G.B., Shaw K.R., Ozenberger B.A., Ellrott K., Shmulevich I., Sander C., Stuart J.M. The Cancer Genome Atlas Pan-Cancer analysis project. Nat. Genet. 2013, 45:1113-1120. Cancer Genome Atlas Research Network.
53. Wolfsgruber W., Feil S., Brummer S., Kuppinger O., Hofmann F., Feil R. A proatherogenic role for cGMP-dependent protein kinase in vascular smooth muscle cells. Proc. Natl. Acad. Sci. USA 2003, 100:13519-13524.
54. Ying L., Hofseth L.J. An emerging role for endothelial nitric oxide synthase in chronic inflammation and cancer. Cancer Res. 2007, 67:1407-1410.
55. Zhang X., Yan G., Ji J., Wu J., Sun X., Shen J., Jiang H., Wang H. PDE5 inhibitor promotes melanin synthesis through the PKG pathway in B16 melanoma cells. J. Cell. Biochem. 2012, 113:2738-2743.
56. Zhang J., Zhao Z., Wang J. Natriuretic peptide receptor A as a novel target for cancer. World J. Surg. Oncol. 2014, 12:174.
57. Zhu B., Vemavarapu L., Thompson W.J., Strada S.J. Suppression of cyclic GMP-specific phosphodiesterase 5 promotes apoptosis and inhibits growth in HT29 cells. J. Cell. Biochem. 2005, 94:336-350.